Name | Type | Description | Interventions |
---|
Arm A (Part 1) | Experimental | Peptide Vaccine (LPV7) + Tetanus peptide + IFA administered in one skin location rotated to different sites on an extremity clinically uninvolved with melanoma.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78. | - Peptide Vaccine (LPV7) + Tetanus peptide
|
Arm B (Part 1) | Experimental | Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78. | - Peptide Vaccine (LPV7) + Tetanus peptide
|
Arm C (Part 1) | Experimental | Peptide Vaccine (LPV7) + Tetanus peptide vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Resiquimod will be applied to the vaccine site immediately after the vaccine administration.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78. | - Peptide Vaccine (LPV7) + Tetanus peptide
|
Arm D (Part 1) | Experimental | Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Resiquimod will be applied to the vaccine site immediately after vaccine administration.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78. | - Peptide Vaccine (LPV7) + Tetanus peptide
|
Arm E (Part 1) | Experimental | Peptide Vaccine (LPV7) + Tetanus peptide + IFA + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78. | - Peptide Vaccine (LPV7) + Tetanus peptide
|
Arm F (Part 1) | Experimental | Peptide Vaccine (LPV7) + Tetanus peptide + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Resiquimod will be applied to the vaccine site immediately after vaccine administration.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78. | - Peptide Vaccine (LPV7) + Tetanus peptide
|
Arm G(Part 1) | Experimental | Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
Resiquimod will be applied to the vaccine site immediately after vaccine administration.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78. | - Peptide Vaccine (LPV7) + Tetanus peptide
|
Arm E2 | Experimental | Peptide Vaccine (LPV7) + IFA + PolyICLC vaccines administered in one skin location. Each vaccine will be administered in the same skin site for all 6 vaccines.
Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78. | - Peptide Vaccine (LPV7) + Tetanus peptide
|